Lyell Immunopharma Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

LYEL$16.75+8.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders Equity

	Three Months Ended June 30, 2024
Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance as of March 31, 2024	254,927	$25	$1,666,315	$(404)	$(1,062,779)	$603,157
Issuance of common stock upon exercise of stock options	377	1	51	—	—	52
Issuance of common stock under employee stock purchase plan	491	—	810	—	—	810
Issuance of common stock in connection with restricted stock units, net of tax	153	—	—	—	—	—
Stock-based compensation	—	—	8,284	—	—	8,284
Other comprehensive income	—	—	—	7	—	7
Net loss	—	—	—	—	(45,809)	(45,809)
Balance as of June 30, 2024	255,948	$26	$1,675,460	$(397)	$(1,108,588)	$566,501

	Six Months Ended June 30, 2024
Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 2023	253,958	$25	$1,657,133	$(94)	$(1,002,112)	$654,952
Issuance of common stock upon exercise of stock options	1,246	1	154	—	—	155
Issuance of common stock under employee stock purchase plan	491	—	810	—	—	810
Issuance of common stock in connection with restricted stock units, net of tax	253	—	(76)	—	—	(76)
Stock-based compensation	—	—	17,439	—	—	17,439
Other comprehensive loss	—	—	—	(303)	—	(303)
Net loss	—	—	—	—	(106,476)	(106,476)
Balance as of June 30, 2024	255,948	$26	$1,675,460	$(397)	$(1,108,588)	$566,501

Condensed Consolidated Statements of Stockholders’ Equity

	Three Months Ended June 30, 2023
Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensive Loss · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance as of March 31, 2023	249,609	$25	$1,622,119	$(3,879)	$(834,439)	$783,826
Issuance of common stock upon exercise of stock options	833	—	83	—	—	83
Issuance of common stock under employee stock purchase plan	543	—	1,163	—	—	1,163
Issuance of common stock in connection with restricted stock units, net of tax	42	—	(50)	—	—	(50)
Stock-based compensation	—	—	14,223	—	—	14,223
Other comprehensive income	—	—	—	1,500	—	1,500
Net loss	—	—	—	—	(63,890)	(63,890)
Balance as of June 30, 2023	251,027	$25	$1,637,538	$(2,379)	$(898,329)	$736,855

	Six Months Ended June 30, 2023
Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensive Loss · AccumulatedDeficit · Total Stockholders’Equity
Shares · Amount
Balance as of December 31, 2022	249,567	$25	$1,608,306	$(7,599)	$(767,480)	$833,252
Issuance of common stock upon exercise of stock options	833	—	83	—	—	83
Issuance of common stock under employee stock purchase plan	543	—	1,163	—	—	1,163
Issuance of common stock in connection with restricted stock units, net of tax	84	—	(119)	—	—	(119)
Stock-based compensation	—	—	28,105	—	—	28,105
Other comprehensive income	—	—	—	5,220	—	5,220
Net loss	—	—	—	—	(130,849)	(130,849)
Balance as of June 30, 2023	251,027	$25	$1,637,538	$(2,379)	$(898,329)	$736,855

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.